

## Special Issue

# BCG Vaccine and Beyond: Innovations in Tuberculosis Vaccination and Inflammation- Related Disease Prevention

### Message from the Guest Editors

This Special Issue aims to gather articles presenting state-of-the-art research, novel discoveries, and the latest progress of novel tuberculosis vaccines and vaccination in pre-clinical and clinical studies. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- Novel approaches to improve the protective efficacy of current TB vaccines;
- Novel vaccine delivery methods;
- Novel insights and approaches to TB vaccine development in pre-clinical and clinical studies;
- Immune correlates of protection studies in tuberculosis vaccine research;
- The role of vaccine-induced innate immune memory in tuberculosis vaccines;
- The role of tissue-resident memory cells in tuberculosis vaccines.

---

### Guest Editors

Prof. Dr. Xiao-Yong Fan

Shanghai Institute of Infectious Diseases and Biosecurity, Fudan University, Shanghai, China

Prof. Dr. Zhi-Dong Hu

Shanghai Public Health Clinical Center, Fudan University, Shanghai, China

---

### Deadline for manuscript submissions

30 April 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/234935](https://mdpi.com/si/234935)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).